Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-01-02 | Reverse | 1:30 |
Co-Diagnostics, Inc. develops and sells molecular diagnostic reagents and platforms for detecting infectious diseases, cancer, and agricultural traits globally, including portable PCR devices for point-of-care and at-home testing.

The Co-Dx PCR Platform is a portable, at-home and point-of-care molecular diagnostics system, serving as Co-Diagnostics' flagship product to make PCR testing more accessible, pending regulatory approval.
| Icon | PRODUCT | Q2-2025 | Q3-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Product | — | — | $145.95K | $166.13K ▲ |
![]() | Product Revenue | $162.91K | $145.38K ▼ | — | — |
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $136.74K | $241.72K ▲ | $81.05K ▼ | $105.39K ▲ |
![]() | NonUS | $8.64K | $32.3K ▲ | $64.9K ▲ | $60.74K ▼ |
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
DWTX | $2.49 | COMPARE |
ADGM | $0.65 | COMPARE |
SINT | $1.55 | COMPARE |
VVOS | $0.30 | COMPARE |
XAIR | $5.04 | COMPARE |
TNON | $6.83 | COMPARE |
AEMD | $2.73 | COMPARE |
PRPH | $0.02 | COMPARE |